- Raised $2.6M grant, Sep 2019
- Raised funding round, Aug 2021
- Raised funding round, Sep 2018
About
Tarsier Pharma is a late-clinical-stage company dedicated to the development and commercialization of a breakthrough therapeutic approach for better and safer treatment of autoimmune inflammatory ocular diseases. The TRS Platform Technology is a bio-inspired immunomodulator designed to treat blinding inflammatory ocular diseases. It is currently being developed as both eye drops and intravitreal injections. TRS has the potential to effectively control a range of autoimmune and inflammatory ocular diseases as potently as steroids but without the negative side effects. The company's investors include a wholly owned subsidiary company of Sun Pharmaceutical Industries Limited, BioLight Life Sciences Ltd, as well as private investors and family offices. The company has also received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No. 879598.
Funding history · 3 rounds · $5.7M total
Q&A
- What is Tarsier Pharma's primary focus?
- Tarsier Pharma is a late-clinical-stage company focused on developing and commercializing novel therapeutic approaches for autoimmune inflammatory ocular diseases.
- What is the core technology behind Tarsier Pharma's treatments?
- Tarsier Pharma's core technology is the TRS Platform Technology, a bio-inspired immunomodulator designed to treat blinding inflammatory ocular diseases. It is being developed as both eye drops and intravitreal injections.
- When was Tarsier Pharma founded?
- Tarsier Pharma was founded in January 2016.
- How many employees does Tarsier Pharma have?
- Tarsier Pharma has 11-50 employees.
- Who are some of the investors in Tarsier Pharma?
- Investors in Tarsier Pharma include a wholly owned subsidiary of Sun Pharmaceutical Industries.
- Has Tarsier Pharma received any grant funding?
- Yes, Tarsier Pharma received a grant of $2,650,000 from the EU Horizon 2020 program in September 2019.
- What is Tarsier Pharma's current product stage?
- Tarsier Pharma's products are currently in the clinical trial stage.
- Who is the CEO of Tarsier Pharma?
- Daphne Haim-Langford, Ph.D. is the Co-Founder & CEO of Tarsier Pharma.
Team · 1
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | tarsierpharma.com |
|---|---|
| linkedin.com/company/34220421 |
Identifiers & details
| Former names | Tarsius Pharma |
|---|---|
| Founded | 2016-1 |
| Employees (exact) | 12 |
Radar intelligence
Patents
| EPO | 6 |
|---|
Web history (Wayback)
| Domain | tarsierpharma.com |
|---|
Certificate / subdomain footprint
| Subdomains | 12 |
|---|